Bayer will offer Veracyte's Afirma Xpression Atlas to identify underlying drivers in tumors of late-stage or metastatic thyroid cancer patients resistant to radioactive iodine therapy.
Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.
The firm will use the proceeds for working capital and other general corporate purposes, with the potential to acquire or invest in complementary businesses, technologies, or assets.
MaviDx will develop, validate, secure regulatory approvals for, and commercialize its SARS-CoV-2 and other infectious disease tests, including for influenza, on Veracyte's nCounter system.
The GenomeWeb Index rose more than 9 percent in May, following an 18 percent climb in April, a marked contrast to its negative performance in February and March.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.